ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,303.27
      0.12%
      US Tech 100
      18,062.00
      -0.10%
      Dow Jones
      40,003.59
      0.34%
      Brent Oil
      83.76
      0.00%
      Bitcoin
      67,000.01
      -0.12%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Alzamend Neuro Inc (ALZN)

      7. Alzamend Neuro Inc (ALZN) News

      ALZN

      Alzamend Neuro (ALZN)

      Alzamend Neuro Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:ALZN
      DateTimeSourceHeadlineSymbolCompany
      3:00PMiHub NewswireFeaturedMusic Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements
      05/16/20244:30PMEdgar (US Regulatory)Form 5 - Annual statement of changes in beneficial ownership of securitiesNASDAQ:ALZNAlzamend Neuro Inc
      05/14/20248:00AMBusiness WireAlzamend Neuro Announces Initial Closing of Private PlacementNASDAQ:ALZNAlzamend Neuro Inc
      05/13/20244:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
      05/10/20245:06PMEdgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:ALZNAlzamend Neuro Inc
      05/10/20244:30PMEdgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:ALZNAlzamend Neuro Inc
      05/10/20246:30AMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ALZNAlzamend Neuro Inc
      05/09/20244:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
      05/09/20244:20PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
      05/09/20248:00AMBusiness WireAlzamend Neuro Announces Agreement for Registered Direct Offering and Concurrent Private Placement for an Aggregate of up to $25 MillionNASDAQ:ALZNAlzamend Neuro Inc
      05/07/20244:31PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ALZNAlzamend Neuro Inc
      05/07/20244:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
      05/07/20248:00AMBusiness WireAlzamend Neuro Announces Termination of At-the-Market Equity Offering ProgramNASDAQ:ALZNAlzamend Neuro Inc
      03/07/20244:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
      02/02/20244:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
      01/05/20244:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
      12/15/20234:30PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ALZNAlzamend Neuro Inc
      12/11/20238:00AMBusiness WireAlzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder PatientsNASDAQ:ALZNAlzamend Neuro Inc
      11/20/20238:00AMBusiness WireAlzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder PatientsNASDAQ:ALZNAlzamend Neuro Inc
      11/16/20234:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
      11/16/20238:00AMBusiness WireAlzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price RequirementNASDAQ:ALZNAlzamend Neuro Inc
      11/13/20238:00AMBusiness WireAlzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Post-Traumatic Stress Disorder Patients of Next‑Generation Lithium Therapeutic Drug Candidate AL001NASDAQ:ALZNAlzamend Neuro Inc
      10/30/20234:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
      10/30/20238:00AMBusiness WireAlzamend Neuro Announces Reverse Stock SplitNASDAQ:ALZNAlzamend Neuro Inc
      10/23/20238:00AMBusiness WireAlzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Major Depressive Disorder Patients of its Next‑Generation Lithium Therapeutic Drug Candidate AL001NASDAQ:ALZNAlzamend Neuro Inc
      10/02/20238:00AMBusiness WireAlzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder PatientsNASDAQ:ALZNAlzamend Neuro Inc
      09/29/20234:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
      09/26/20236:01PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALZNAlzamend Neuro Inc
      09/22/20234:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
      09/22/20238:00AMBusiness WireAlzamend Neuro Granted Extension by Nasdaq Panel to Regain Compliance with the Minimum Bid Price Continued Listing RequirementNASDAQ:ALZNAlzamend Neuro Inc
       Showing the most relevant articles for your search:NASDAQ:ALZN